Dr. Lal PathLabs Board to Consider Q2 FY27 Results, Dividend

This is a regulatory disclosure addressed to the National Stock Exchange of India Limited and BSE Limited. It serves as a follow-up to an earlier intimation dated September 25, 2026.

The Board of Directors of Dr. Lal PathLabs Limited is scheduled to meet on Wednesday, November 04, 2026. The agenda for the meeting includes two key items:

1. To consider and approve the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2026.

2. To consider declaring a second interim dividend, if any, on the Equity Shares of the Company for the Financial Year 2026-27.

The intimation was signed by Vinay Gujral, Company Secretary & Compliance Officer, on October 27, 2026. The financial impact of the potential dividend is not quantified in this disclosure, as its declaration is subject to board approval.